Radzikowska Elżbieta, Roszkowski-Śliż Kazimierz, Głaz Piotr
National Tuberculosis and Lung Diseases Research Institute, Plocka 26 St., 01–138 Warsaw, Poland.
Pneumonol Alergol Pol. 2012;80(5):422-9.
It is uncertain whether timeliness improves clinical outcomes in lung cancer patients. The goal of the study was to analyse the influence of patient's and doctor's delays on survival of unselected population of NSCLC patients.
From 1995 to 1998, 8705 squamous cell lung cancer patient's and 1881 adenocarcinoma patient's were registered in Pulmonary Outpatients Clinics in all parts of Poland and subsequently in National Tuberculosis and Lung Diseases Research Institute Register (NTLDRIR).
The median time from first symptom(s) to the beginning of a treatment was 92 days (mean -138.5 days).The median waiting time between first symptom(s) and first visit to a doctor's was 30 days (mean 57 days) and from first visit to a doctor's to referral to a chest physician - was 17 days (mean 41days). Diagnosis of the NSCLC was established in a mean time of 71 days (median 40 days), but chest physician diagnosed patients in a mean time of 51days (median 28 days). The multivariate analysis revealed that ECOG performance status (PS) 2 (HR = 1.4) and 3+4 (HR = 2.23), clinical stage of the disease II (HR = 1.32), III (HR = 1.41), and IV (HR = 1.82) were independent negative predictors of survival. Non-surgically treated patients had worse prognosis than patients treated surgically (HR = 3.03). Lack of patient's delay had a significant positive impact on survival (HR = 0.88), particularly for patients in PS 0+1 (HR = 0.9) and 3+4 (HR = 0.9). Lack of doctor's delay was a negative predictive factor of survival (HR = 1.14). It was observed particularly in patients in performance status 2 (HR = 1.28).
The patient's delay and lack of doctor's delay had a negative impact on survival of NSCLC patients.
肺癌患者的及时性是否能改善临床结局尚不确定。本研究的目的是分析患者延误和医生延误对未经选择的非小细胞肺癌(NSCLC)患者生存的影响。
1995年至1998年,波兰各地的肺部门诊诊所登记了8705例鳞状细胞肺癌患者和1881例腺癌患者,随后将其纳入国家结核病和肺部疾病研究所登记处(NTLDRIR)。
从出现首个症状到开始治疗的中位时间为92天(平均138.5天)。从出现首个症状到首次就诊的中位等待时间为30天(平均57天),从首次就诊到转诊至胸科医生的中位等待时间为17天(平均41天)。NSCLC的诊断平均用时71天(中位时间40天),但胸科医生诊断患者的平均用时为51天(中位时间28天)。多因素分析显示,东部肿瘤协作组(ECOG)体能状态(PS)为2(风险比[HR]=1.4)和3+4(HR=2.23)、疾病临床分期为II期(HR=1.32)、III期(HR=1.41)和IV期(HR=1.82)是生存的独立负性预测因素。非手术治疗患者的预后比手术治疗患者差(HR=3.03)。患者无延误对生存有显著的积极影响(HR=0.88),尤其是PS为0+1(HR=0.9)和3+4(HR=0.9)的患者。医生无延误是生存的负性预测因素(HR=1.14)。这在体能状态为2的患者中尤为明显(HR=1.28)。
患者延误和医生无延误对NSCLC患者的生存有负面影响。